Preliminary study of WR 33063 in the treatment of falciparum malaria in northeast Thailand.
D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000032:analysis; D000962:Antimalarials / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004983:Ethanolamines / Q000009:adverse effects / Q000627:therapeutic use; D005334:Fever / Q000209:etiology; D005500:Follow-Up Studies; D006400:Hematocrit; D006801:Humans; D007677:Kidney Function Tests; D007958:Leukocyte Count; D008111:Liver Function Tests; D008288:Malaria / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010270:Parasite Egg Count; D010616:Phenanthrenes / Q000009:adverse effects / Q000627:therapeutic use*; D010963:Plasmodium falciparum / Q000187:drug effects*; D011803:Quinine / Q000009:adverse effects / Q000627:therapeutic use; D013785:Thailand
D000906:Antibodies; D000962:Antimalarials; D004983:Ethanolamines; D010616:Phenanthrenes; D011803:Quinine